Centessa Pharmaceuticals (CNTA) Cash & Equivalents (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Cash & Equivalents data on file, last reported at $62.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $62.4 million, down 40.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.4 million (down 40.63% YoY), and the FY2025 annual result was $61.3 million, down 84.0% from the prior year.
• Cash & Equivalents advanced to $62.4 million in Q1 2026 per CNTA's latest filing, from $61.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $544.5 million in Q1 2022 and troughed at $44.2 million in Q2 2025.
• A 5-year average of $230.6 million and a median of $145.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 199.32% in 2024, then tumbled 87.14% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $393.6 million in 2022, then sank by 67.48% to $128.0 million in 2023, then soared by 199.32% to $383.2 million in 2024, then tumbled by 84.0% to $61.3 million in 2025, then increased by 1.85% to $62.4 million in 2026.
• Business Quant data shows CNTA's Cash & Equivalents at $62.4 million in Q1 2026, $61.3 million in Q4 2025, and $50.8 million in Q3 2025.